Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis

The World Health Organization (WHO) has formally recommended long-acting injectable lenacapavir (LEN), administered twice yearly, as a highly effective additional option for HIV pre-exposure prophylaxis (PrEP). This significant endorsement is poised to expand the global PrEP market by increasing uptake, signaling a positive development for pharmaceutical companies manufacturing LEN and other long-acting PrEP drugs like cabotegravir, alongside companies providing rapid diagnostic tests. The guidelines also highlight ongoing research into cost-effectiveness and drug resistance.

Analysis

The World Health Organization (WHO) has issued a formal guideline recommending the twice-yearly long-acting injectable lenacapavir (LEN) as an additional option for HIV pre-exposure prophylaxis (PrEP). This endorsement is significant as it validates a new, highly effective prevention method aimed at increasing overall PrEP uptake by expanding patient choice. The recommendation is expected to positively impact manufacturers of LEN and other long-acting PrEP treatments, such as cabotegravir (CAB-LA), by potentially expanding the total addressable market. Furthermore, the guideline explicitly links the rollout of these injectables to the use of HIV rapid diagnostic tests (RDTs), signaling a potential demand increase for diagnostic companies. However, the accompanying annexes highlight critical implementation hurdles, including the need to evaluate cost-effectiveness and manage the risk of drug resistance. These factors will be crucial for widespread adoption by national health programs and will likely dictate the ultimate commercial success and market penetration of these new therapies.

Key Decisions for Investors

• Investors should view this WHO recommendation as a long-term tailwind for the long-acting injectable drug market, particularly for companies with pipelines in HIV prevention.
• Consider exposure to manufacturers of HIV rapid diagnostic tests, as their use is now formally recommended by the WHO for monitoring patients on new long-acting PrEP regimens.
• Monitor upcoming data and policy decisions related to the cost-effectiveness and drug resistance profiles of lenacapavir, as these factors will be critical determinants of its adoption rate and commercial viability.